Neonatal Alloimmune Thrombocytopenia

Hematology
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusionN/A1 trial
Active Trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Qilu PharmaceuticalStandard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion

Clinical Trials (1)

NCT02934906Qilu PharmaceuticalStandard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion

Study on the Anti-HPA Antibodies Caused Neonatal Alloimmune Thrombocytopenia in Chinese Pregnant Women

Start: Jan 2017
N/AUnknown

Related Jobs in Hematology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space